-
- Scott J. Callahan
- Memorial Sloan Kettering Cancer Center 1 , Cancer Biology and Genetics and Department of Medicine, New York, NY 10065 , USA
-
- Stephanie Tepan
- Memorial Sloan Kettering Cancer Center, 2017 Summer Clinical Oncology Research Experience (SCORE) Program 4 , New York, NY 10065 , USA
-
- Yan M. Zhang
- Memorial Sloan Kettering Cancer Center 1 , Cancer Biology and Genetics and Department of Medicine, New York, NY 10065 , USA
-
- Helen Lindsay
- Institute of Molecular Life Sciences, University of Zurich 6 , Zurich 8057 , Switzerland
-
- Alexa Burger
- Institute of Molecular Life Sciences, University of Zurich 6 , Zurich 8057 , Switzerland
-
- Nathaniel R. Campbell
- Weill Cornell/Rockefeller/Sloan-Kettering Tri-Institutional MD-PhD Program 8 , New York, NY 10065 , USA
-
- Isabella S. Kim
- Memorial Sloan Kettering Cancer Center 1 , Cancer Biology and Genetics and Department of Medicine, New York, NY 10065 , USA
-
- Travis J. Hollmann
- Memorial Sloan Kettering Cancer Center 9 , Pathology, New York, NY 10065 , USA
-
- Lorenz Studer
- The Center for Stem Cell Biology, Sloan Kettering Institute 10 , New York, NY 10065 , USA ; Developmental Biology Program , , New York, NY 10065 , USA
-
- Christian Mosimann
- Institute of Molecular Life Sciences, University of Zurich 6 , Zurich 8057 , Switzerland
-
- Richard M. White
- Memorial Sloan Kettering Cancer Center 1 , Cancer Biology and Genetics and Department of Medicine, New York, NY 10065 , USA
説明
<jats:title>ABSTRACT</jats:title> <jats:p>Transgenic animals are invaluable for modeling cancer genomics, but often require complex crosses of multiple germline alleles to obtain the desired combinations. Zebrafish models have advantages in that transgenes can be rapidly tested by mosaic expression, but typically lack spatial and temporal control of tumor onset, which limits their utility for the study of tumor progression and metastasis. To overcome these limitations, we have developed a method referred to as Transgene Electroporation in Adult Zebrafish (TEAZ). TEAZ can deliver DNA constructs with promoter elements of interest to drive fluorophores, oncogenes or CRISPR-Cas9-based mutagenic cassettes in specific cell types. Using TEAZ, we created a highly aggressive melanoma model via Cas9-mediated inactivation of Rb1 in the context of BRAFV600E in spatially constrained melanocytes. Unlike prior models that take ∼4 months to develop, we found that TEAZ leads to tumor onset in ∼7 weeks, and these tumors develop in fully immunocompetent animals. As the resulting tumors initiated at highly defined locations, we could track their progression via fluorescence, and documented deep invasion into tissues and metastatic deposits. TEAZ can be deployed to other tissues and cell types, such as the heart, with the use of suitable transgenic promoters. The versatility of TEAZ makes it widely accessible for rapid modeling of somatic gene alterations and cancer progression at a scale not achievable in other in vivo systems.</jats:p>
収録刊行物
-
- Disease Models & Mechanisms
-
Disease Models & Mechanisms 11 (9), 2018-09-01
The Company of Biologists